

# 1 **Lack of genetic evidence for NLRP3-inflammasome** 2 **involvement in Parkinson's disease pathogenesis**

3 Konstantin Senkevich, MD, PhD,<sup>1,2</sup> Lang Liu MSc<sup>1,2,3</sup>, Chelsea X. Alvarado<sup>4,5</sup>, Hampton L.  
4 Leonard, MSc,<sup>4,5,6</sup> Mike A. Nalls, PhD,<sup>4,5</sup>; Global Parkinson's Genetics Program (GP2); Ziv  
5 Gan-Or, MD, PhD<sup>1,2,3</sup>

## 6 **Author affiliations:**

- 7 1. The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal,  
8 Quebec, Canada
- 9 2. Department of Neurology and neurosurgery, McGill University, Montréal, QC,  
10 Canada, Canada
- 11 3. Department of Human Genetics, McGill University, Montréal, QC, Canada
- 12 4. Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging  
13 and National Institute of Neurological Disorders and Stroke, National Institutes of  
14 Health, Bethesda, MD, USA, 20814
- 15 5. Data Tecnica, Washington, DC, USA, 200373.
- 16 6. DZNE Tübingen, Tübingen, Germany

## 17 18 **Abstract**

19 Activation of the NLRP3-inflammasome has been implicated in Parkinson's disease based on  
20 *in vitro* and *in vivo* studies. Clinical trials targeting the NLRP3-inflammasome in Parkinson's  
21 disease are ongoing. However, the evidence supporting NLRP3's involvement in Parkinson's  
22 disease from human genetics data is limited. In this study, we conducted analyses of common  
23 and rare variants in NLRP3-inflammasome related genes in Parkinson's disease cohorts. We  
24 performed pathway-specific analyses using polygenic risk scores and studied potential causal  
25 associations using Mendelian randomization with the NLRP3 components and the cytokines  
26 IL-1 $\beta$  and IL-18. Our findings showed no associations of common or rare variants, nor of the  
27 pathway polygenic risk score with Parkinson's disease. Mendelian randomization suggests  
28 that altering the expression of the NLRP3-inflammasome, IL-1 $\beta$  or IL-18, does not affect  
29 Parkinson's disease risk or progression. Therefore, our results do not support a role for the  
30 NLRP3-inflammasome in Parkinson's disease pathogenesis or as a target for drug  
31 development.

32 Correspondence to:

33 Ziv Gan-Or

34 McGill University

35 1033 Pine Avenue, West,

1 Ludmer Pavilion, room 312

2 Montreal, QC, H3A 1A1,

3 Phone: +1-514-398-5845

4 Fax. +1-514 398-8248

5 Email: [ziv.gan-or@mcgill.ca](mailto:ziv.gan-or@mcgill.ca)

6

7 **Keywords:** Parkinson's disease, clinical trials, NLRP3, genetics, inflammation

8 **Running title:** NLRP3 genetics: Limited druggability in Parkinson's disease

9

## 1 **Introduction**

2 In recent years, activation of the nucleotide-binding oligomerization domain-, leucine-rich  
3 repeat and pyrin domain-containing 3 (NLRP3) inflammasome has been implicated in  
4 Parkinson's disease by numerous functional studies using different models <sup>1</sup>. Inflammasomes  
5 are protein complexes which serve as signaling platforms for activation of immune response.  
6 The NLRP3 inflammasome comprises three main components: NLRP3 (encoded by the  
7 *NLRP3* gene), apoptosis-associated speck-like protein containing a caspase activating  
8 recruitment domain (encoded by *PYCARD*) and caspase-1 (*CASP1*). NLRP3 is expressed in  
9 microglia and when activated, it leads to secretion of the cytokines IL-1 $\beta$  and IL-18, which  
10 leads to neuroinflammatory response and pyroptosis <sup>2</sup>.

11 The evidence for the involvement of the NLRP3 inflammasome in Parkinson's  
12 disease is mainly derived from *in vitro* and *in vivo* cell and animal models, by interacting  
13 with  $\alpha$ -synuclein, mitochondria and other mechanisms. For example, early research suggested  
14 that in human monocytes,  $\alpha$ -synuclein may directly trigger the NLRP3 inflammasome <sup>3</sup>.  
15 Similar results have been reported in other cell and animal models <sup>4,5</sup>. Other studies in cell  
16 and animal models have suggested that the NLRP3 inflammasome may be involved in toxin-  
17 mediated Parkinson's disease and that there could be an interplay between mitochondria and  
18 the NLRP3 inflammasome in Parkinson's disease pathogenesis <sup>6,7</sup>. In humans, one study  
19 reported that a genetic variant in *NLRP3* may affect its expression and the risk of Parkinson's  
20 disease <sup>8</sup>. Several studies in cells and postmortem brain tissues from Parkinson's disease  
21 patients and controls reported alterations in the NLRP3 inflammasome in Parkinson's disease  
22 <sup>8-10</sup>. However, there are no thorough human genetic studies of the NLRP3 inflammasome in  
23 Parkinson's disease, although such studies can help with inferring causality. Nevertheless,  
24 there is a suggestion that the NLRP3 inflammasome may be a good target for therapeutic  
25 development in Parkinson's disease, and several compounds targeting the NLRP3  
26 inflammasome are in different stages of development <sup>11</sup>. Considering that clinical trial

1 success rates increase significantly when supported by genetic evidence <sup>12</sup>, it becomes crucial  
2 to conduct thorough genetic analysis of the proposed target.

3 In this study, we aimed to examine whether human genetics data supports NLRP3  
4 involvement in Parkinson's disease and development of therapeutics targeting NLRP3 for  
5 Parkinson's disease. We analyzed common and rare variants in the NLRP3 inflammasome  
6 components in large Parkinson's disease cohorts, and further performed pathway specific  
7 analyses of polygenic risk scores (PRS) and Mendelian randomization (MR) analyses. Our  
8 results do not support an important role for the NLRP3 inflammasome in Parkinson's disease  
9 nor its being a good target for therapeutic development in sporadic Parkinson's disease.

10

## 1 **Results**

### 2 **No association between NLRP3 inflammasome genes and** 3 **Parkinson's disease**

4 We examined common variants from the largest available Parkinson's disease risk GWAS (N  
5 cases/proxy-cases= 49,053; N controls= 1,411,006)<sup>13</sup>. We did not observe any associations  
6 between Parkinson's disease and variants in genes composing the NLRP3 complex (*NLRP3*,  
7 *PYCARD* and *CASP1*) and the genes encoding the cytokines released by its activation, *IL-1 $\beta$*   
8 and *IL-18* in neither GWAS on participants from European ancestry nor the diverse non-  
9 European Global Parkinson's Genetics Program (GP2) cohorts (Fig. 1; Supplementary Figure  
10 1). While the *PYCARD* gene is located near one of the GWAS loci (rs11150601) within  
11 *SETD1A*, *PYCARD* is just outside of the linkage disequilibrium (LD) block, i.e. there are no  
12 variants within or in regulatory regions of *PYCARD* that are in LD ( $r^2 < 0.2$ ) with the variants  
13 that surpassed the GWAS level of significance. We then performed PRS analyses for the  
14 three NLRP3 inflammasome genes from 14,828 Parkinson's disease cases and 13,283  
15 controls across 7 cohorts (detailed in Supplementary Table 1). Overall, the PRS explains a  
16 very small portion of the variance in Parkinson's disease ( $1.39E-06-0.001$ ) and was not  
17 associated with Parkinson's disease (Fig. 2, Supplementary Table 2).

18 We also analyzed rare variants in two independent cohorts, including 2,943 patients  
19 and 18,486 controls, followed by a meta-analysis (Supplementary Table 3). We did not  
20 observe any associations between any subsets of variants in any of the genes comprising the  
21 NLRP3 inflammasome and Parkinson's disease (Supplementary Table 4). We then performed  
22 an analysis including all the variants in all three genes combined, and in this analysis too, we  
23 did not observe any associations between rare variants and Parkinson's disease  
24 (Supplementary Table 4).

## 1 Mendelian randomization does not support NLRP3 as a 2 druggable target for Parkinson's disease.

3 Using summary-data-based Mendelian Randomization (SMR), we investigated whether the  
4 modulation of the NLRP3 inflammasome could be a target for therapy. Initially, we  
5 established that *NLRP3*, *CASPI*, *IL-1 $\beta$* , *IL-18* are recognized within the database of  
6 druggable genes, highlighting their potential relevance for drug development <sup>14</sup>. PYCARD,  
7 however, did not meet these criteria. We then performed SMR, where exposure were  
8 Quantitative trait loci (QTL) of NLRP3 genes from tissues that are relevant to Parkinson's  
9 disease pathogenesis. In the present study, we used the Genotype-Tissue Expression (GTEx)  
10 project v8 release (All brain tissues, blood and liver), PsychENCODE, and BrainMeta/brain-  
11 eMeta <sup>15-17</sup>. As an outcome for SMR, we used the most recent Parkinson's disease risk <sup>13</sup>,  
12 Parkinson's disease age-at-onset <sup>18</sup> GWASs and largest publicly available Parkinson's disease  
13 motor and cognitive progression GWASs <sup>19,20</sup>. Our analysis did not reveal any potential  
14 causal associations between the QTL data tested in this study and Parkinson's disease in  
15 tissues relevant for Parkinson's disease after correction for multiple comparisons  
16 (Supplementary Table 5).

17

## 1 **Discussion**

2 Our results, using large-scale human genetic, transcriptomic and methylomic data, do not  
3 support the NLRP3 inflammasome as important in Parkinson's disease pathogenesis or as a  
4 good target for drug development. There were no associations of common or rare variants,  
5 nor of polygenic risk score for the NLRP3 inflammasome, with risk of Parkinson's disease.  
6 When we considered the three NLRP3 genes as druggable targets, there was no evidence that  
7 altering their expression at the RNA level may have an effect on risk, onset or Parkinson's  
8 disease progression.

9 While using MR to infer efficient druggability is not a definitive test, it can still  
10 provide valuable information. For example, a recent MR study was able to replicate the  
11 beneficial effects of tumor necrosis factor (TNF) inhibition in Crohn's disease and ulcerative  
12 colitis, and its deleterious effect in multiple sclerosis <sup>21</sup>. The same study also suggested that  
13 TNF inhibition might not be beneficial for Parkinson's disease.

14 Understanding the role of a drug compound is essential when planning clinical trials.  
15 Studies that are not guided by genetic evidence are more likely to fail <sup>12</sup>. Currently, several  
16 phase 1 clinical trials targeting neuroinflammation and particularly NLRP3-inflamassome are  
17 being conducted <sup>22</sup>. The discordance between the hypothesis underlying these clinical trials  
18 targeting NLRP3 pathway in Parkinson's disease and our findings suggests that efforts to  
19 target the NLRP3 inflammasome in Parkinson's disease should be critically evaluated. It is  
20 important to select therapeutic strategies based on robust human genetic and biomarker  
21 evidence to reduce chances of trial failure. Perhaps targeting the NLRP3 inflammasome  
22 could work specifically in individuals in which this pathway is pathologically activated, but  
23 this approach is not being taken to the best of our knowledge. Subpopulations of patients with  
24 distinct genetic or environmental risk factors where the NLRP3 pathway plays a role in  
25 disease pathogenesis may exist. However, additional effort on defining subpopulation of  
26 Parkinson's disease patients with neuroinflammation and particularly with induction of the

1 NLRP3 pathway should be considered in clinical research targeting the NLRP3  
2 inflammasome. Future studies exploring potential gene-environment interactions may further  
3 explain the role of the NLRP3 inflammasome in specific subsets of Parkinson's disease  
4 patients.

5 Our study has several limitations that need to be acknowledged. The GWASs on  
6 Parkinson's disease progression that were used could be underpowered. Further analysis  
7 using larger datasets should be performed when they become available to confirm our  
8 findings. Another important limitation of our study is the reliance solely on genetic and  
9 transcriptomic data to infer the role and druggability of the NLRP3 inflammasome in  
10 Parkinson's disease. This approach does not account for post-translational modifications and  
11 the complex regulation at the protein level, which are critical for the functional activity of the  
12 NLRP3 inflammasome. Finally, the SMR analysis is dependent on the quality of the  
13 expression data used for exposure, and variations in quality across datasets might influence  
14 the results.

15 In conclusion, our analyses do not provide human genetic evidence for the  
16 involvement of the NLRP3 inflammasome in Parkinson's disease, suggesting potentially  
17 limited druggability from genetic perspective.

18



## 1 **Online Methods**

### 2 **Study populations**

3 To examine whether common variants in the NLRP3 inflammasome components may be  
4 associated with Parkinson's disease, we used summary statistics from the largest European  
5 Parkinson's disease GWAS<sup>13</sup> and also analyzed genes of interest using the data from GP2  
6 (release six) in several ancestry populations (detailed in Supplementary Table 6). Quality  
7 control analyses for both samples and variants have been previously described  
8 (<https://github.com/GP2code/GenoTools>). To study the association of common variants  
9 (minor allele frequency > 1%) with Parkinson's disease in GP2 cohorts, we performed  
10 logistic regression, adjusting for age, sex, and the top five principal components in each  
11 ancestral population. For each of the cohorts, we created locus zoom plots using locuszoomr  
12 R library<sup>23</sup> for the *NLRP3*, *CASPI*, *PYCARD*, *IL-1 $\beta$*  and *IL-18*, loci with +/- 500kb around  
13 each gene. We then created pathway specific PRS for the NLRP3 inflammasome using  
14 available individual level data from cohorts of European ancestry (detailed in Supplementary  
15 Table 1).

16 In our Mendelian randomization analysis, we utilized the following summary  
17 statistics datasets: Parkinson's disease risk GWAS<sup>13</sup>, Parkinson's disease age-at-onset  
18 GWAS with 17,415 cases<sup>18</sup>, and Parkinson's disease progression data from GWAS studies  
19 conducted by Iwaki et al.<sup>19</sup> and Tan et al.<sup>20</sup>. The Parkinson's disease progression traits in the  
20 study by Iwaki et al.<sup>19</sup> were measured using observational study meta-analysis of clinical  
21 scales data, we specifically used UPDRS Part III (N cases = 1,398), MMSE (N cases =  
22 1,329), and MoCA (N cases = 1,000) scores. In the study by Tan et al.<sup>20</sup>, Parkinson's disease  
23 progression was assessed using scores for motor, cognitive, and composite progression in  
24 3,364 Parkinson's disease patients with an average follow-up of 4.2 years.

1 To analyze rare variants, we performed analysis in two cohorts with available whole-  
2 exome and whole-genome sequencing data with a total of 2,943 Parkinson's disease patients  
3 and 18,486 controls (Supplementary Table 3). Whole-genome sequencing was available from  
4 the Accelerating Medicines Partnership – Parkinson Disease (AMP-PD) initiative cohorts  
5 (<https://amp-pd.org/>; detailed in the Acknowledgment). Whole-exome data was available  
6 from the UK biobank (UKBB) cohort which was accessed using Neurohub  
7 (<https://www.mcgill.ca/hbhl/neurohub>).

## 8 **Polygenic risk score pathway analysis**

9 In order to examine the potential genetic association of the NLRP3 complex as a whole in  
10 Parkinson's disease (as opposed to analysis of specific SNPs), we calculated pathway PRS  
11 using PRSet for the three genes encoding the components of the NLRP3 complex (*NLRP3*,  
12 *PYCARD* and *CASPI*)<sup>24</sup>. In this analysis, we only included participants of European origin  
13 and removed first- or second-degree relatives. Sex discrepancy analysis was conducted to  
14 compare the recorded biological sex of individuals in the dataset with their genetically  
15 inferred sex, determined by rates of heterozygosity and homozygosity on the X chromosome.  
16 This analysis used the --check-sex function in PLINK 1.9, where males were expected to  
17 exhibit an X chromosome homozygosity estimate greater than 0.85, and females less than  
18 0.25. This method enabled the identification and exclusion of samples with potential sex  
19 mismatches (where the reported sex at recruitment does not match the genetic sex), thereby  
20 enhancing the accuracy of subsequent genetic analyses. Only common SNPs with minor  
21 allele frequency > 0.01 and p-value < 0.05 were included in the analysis. We conducted LD  
22 clumping, removing variants with  $r^2 > 0.1$  and within a 250kb distance. We performed a  
23 permutation test with 10000 repetitions to generate an empirical p-value for our gene set of  
24 interest. We used age at onset for cases, age at enrollment for controls, sex, and the top 10  
25 principal components as covariates.

## 26 **Whole-exome and whole-genome sequencing data analysis**

1 To determine whether rare variants in the genes encoding the components of the NLRP3  
2 inflammasome (*NLRP3*, *PYCARD* and *CASP1*), we extracted genetic data from whole-exome  
3 and whole-genome sequencing datasets. Our analysis included only participants of European  
4 ancestry, and we excluded any first or second-degree relatives from the study. For whole-  
5 genome sequencing data, we performed quality control as previously described <sup>25</sup>. In brief,  
6 we included samples with a mean coverage of 25x and a rate of missing genotypes per  
7 sample less than 5%. For the UK Biobank's whole-exome sequencing data, we used the  
8 Genome Analysis Toolkit (GATK, v3.8) to perform quality control. We applied the  
9 recommended filtration parameters for whole-exome sequencing data, which included a  
10 minimum depth of coverage of 10x and a minimum genotype quality (GQ) score of 20 <sup>26</sup>.  
11 The human reference genome hg38 was used for alignment.

12 We analyzed the association of rare variants with minor allele frequency <0.01 using  
13 the optimized sequence kernel association test (SKAT-O) <sup>27</sup>. The variants were grouped to  
14 different categories: all rare variants, all non-synonymous variants, loss-of-function variants  
15 (stop, frame-shift and canonical splice-site variants) and variants with a combined annotation  
16 dependent depletion (CADD) score  $\geq 20$  (representing 1% of the top deleterious variants). To  
17 meta-analyze the two cohorts we used the metaSKAT R package <sup>28</sup>.

## 18 **Mendelian randomization**

19 If modulation of the NLRP3 inflammasome is a target for therapy, then genetically driven  
20 differences in its expression, or that of the cytokines released following its activation, IL-1 $\beta$   
21 and IL-18, should be causally linked to Parkinson's disease risk or progression. To examine  
22 this possibility, we used SMR. SMR utilizes summary-level data to determine whether a  
23 causal relationship exists between an exposure and an outcome. In our specific case, we  
24 examined if differences in expression levels of the NLRP3 genes (using quantitative trait loci,  
25 QTL) are associated with risk, age-at onset and progression of Parkinson's disease. As  
26 exposure, we used different QTL data from various studies and tissues including methylation,

1 gene-expression and chromatin QTLs. All the QTLs we used were collected from the same  
2 resource, and we conducted analyses using SMR software developed by Yang Lab with  
3 standard settings (<https://yanglab.westlake.edu.cn>)<sup>29,30</sup>. Specifically GTEx project v8 release  
4 (All brain tissues, blood and liver), PsychENCODE, and BrainMeta/brain-eMeta<sup>15-17</sup>. As an  
5 outcome for SMR, we used the most recent Parkinson's disease risk<sup>13</sup>, Parkinson's disease  
6 age-at-onset<sup>18</sup> GWASs and largest publicly available Parkinson's disease progression  
7 GWASs<sup>19,20</sup>. The Bonferroni-corrected significance threshold was set at  $p <$   
8  $0.05/185=0.00027$ .

## 9 **Data availability**

10 All code is available on our GitHub repository, which can be accessed at  
11 <https://github.com/gan-orlab/NLRP3>. The data used in the preparation of this article were  
12 obtained from the AMP PD Knowledge Platform (<https://www.amp-pd.org>) and the UKBB  
13 via Neurohub (<https://www.mcgill.ca/hbhl/neurohub>). The full GWAS summary statistics for  
14 the 23andMe inc., discovery data set will be made available through 23andMe to qualified  
15 researchers under an agreement with 23andMe that protects the privacy of the 23andMe  
16 participants. Please visit [research.23andme.com/collaborate/](https://research.23andme.com/collaborate/) for more information and to  
17 apply to access the data. QTL data and SMR software are available on the Yang Lab website  
18 (<https://yanglab.westlake.edu.cn>).

19

20

## 1 **Acknowledgements**

2 We would like to thank the participants in the different cohorts for contributing to this study.

3 ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheurs-  
4 boursiers award, in collaboration with Parkinson Quebec, and is a William Dawson Scholar.

5 The KS is supported by a clinical fellowship from the Parkinson Canada. Data used in the  
6 preparation of this article were obtained from the AMP PD Knowledge Platform. For up-to-  
7 date information on the study, visit <https://www.amp-pd.org>. AMP PD – a public-private  
8 partnership – is managed by the FNIH and funded by Celgene, GSK, the Michael J. Fox  
9 Foundation for Parkinson’s Research, the National Institute of Neurological Disorders and  
10 Stroke, Pfizer, Sanofi, and Verily. Genetic data used in preparation of this article were  
11 obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the  
12 Harvard Biomarker Study (HBS), the Parkinson’s Progression Markers Initiative (PPMI), the  
13 Parkinson’s Disease Biomarkers Program (PDBP), the International LBD Genomics  
14 Consortium (iLBDGC), and the STEADY-PD III Investigators. BioFIND is sponsored by  
15 The Michael J. Fox Foundation for Parkinson’s Research (MJFF) with support from the  
16 National Institute for Neurological Disorders and Stroke (NINDS). The BioFIND  
17 Investigators have not participated in reviewing the data analysis or content of the  
18 manuscript. For up-to-date information on the study, visit [michaeljfox.org/news/biofind](http://michaeljfox.org/news/biofind). The  
19 HBS is a collaboration of HBS investigators [full list of HBS investigators found at  
20 <https://www.bwhparkinsoncenter.org/biobank/> and funded through philanthropy and NIH and  
21 Non-NIH funding sources. The HBS Investigators have not participated in reviewing the data  
22 analysis or content of the manuscript. PPMI – a public-private partnership – is funded by the  
23 Michael J. Fox Foundation for Parkinson’s Research and funding partners, including [list the  
24 full names of all of the PPMI funding partners found at [www.ppmi-info.org/fundingpartners](http://www.ppmi-info.org/fundingpartners)].  
25 The PPMI Investigators have not participated in reviewing the data analysis or content of the  
26 manuscript. For up-to-date information on the study, visit [www.ppmi-info.org](http://www.ppmi-info.org). PDBP  
27 consortium is supported by the NINDS at the National Institutes of Health. A full list of

1 PDBP investigators can be found at <https://pdbp.ninds.nih.gov/policy>. The PDBP  
2 investigators have not participated in reviewing the data analysis or content of the  
3 manuscript. Genome Sequencing in Lewy Body Dementia and Neurologically Healthy  
4 Controls: A Resource for the Research Community.” was generated by the iLBDGC, under  
5 the co-directorship by Dr. Bryan J. Traynor and Dr. Sonja W. Scholz from the Intramural  
6 Research Program of the U.S. National Institutes of Health. The iLBDGC Investigators have  
7 not participated in reviewing the data analysis or content of the manuscript. For a complete  
8 list of contributors, please see: bioRxiv 2020.07.06.185066; doi:  
9 <https://doi.org/10.1101/2020.07.06.185066>. STEADY-PD III is a 36-month, Phase 3,  
10 parallel group, placebo-controlled study of the efficacy of isradipine 10 mg daily in 336  
11 participants with early Parkinson’s Disease that was funded by the NINDS and supported by  
12 The Michael J Fox Foundation for Parkinson’s Research and the Parkinson’s Study Group.  
13 The STEADY-PD III Investigators have not participated in reviewing the data analysis or  
14 content of the manuscript. The full list of STEADY PD III investigators can be found at:  
15 <https://clinicaltrials.gov/ct2/show/NCT02168842>. We would also like to thank the research  
16 participants and employees of 23andMe, inc. for making this work possible. The full GWAS  
17 summary statistics for the 23andMe discovery data set will be made available through  
18 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy  
19 of the 23andMe participants. Please visit [research.23andme.com/collaborate/](https://research.23andme.com/collaborate/) for more  
20 information and to apply to access the data. This research used the NeuroHub infrastructure  
21 and was undertaken thanks in part to funding from the Canada First Research Excellence  
22 Fund, awarded through the Healthy Brains, Healthy Lives initiative at McGill University,  
23 Calcul Québec and Compute Canada. This research has been conducted using the UK  
24 Biobank Resource under Application Number 45551. The UKBB cohort was accessed using  
25 Neurohub (<https://www.mcgill.ca/hbhl/neurohub>). This research was supported in part by the  
26 Intramural Research Program of the NIH, National Institute on Aging (NIA), National  
27 Institutes of Health, Department of Health and Human Services; project number

1 ZIAAG000535, as well as the National Institute of Neurological Disorders and Stroke. This  
2 work utilized the computational resources of the NIH HPC Biowulf cluster.  
3 (<http://hpc.nih.gov>). Data used in the preparation of this article were obtained from Global  
4 Parkinson's Genetics Program (GP2). GP2 is funded by the Aligning Science Across  
5 Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for  
6 Parkinson's Research (<https://gp2.org>). The members of the GP2 groups are listed in the  
7 supporting information. For a complete list of GP2 members see <https://gp2.org>.

## 8 **Funding**

9 This work was financially supported by grants from the Michael J. Fox Foundation, the  
10 Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research  
11 Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy  
12 Lives initiative (HBHL), and Parkinson Canada.

## 13 **Competing interests**

14 Z.G.O received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail  
15 Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial,  
16 UCB, Capsida, Vanquabio Guidepoint, Lighthouse and Deerfield. C.X.A., M.A.N. and  
17 H.L.L.'s participation in this project was part of a competitive contract awarded to Data  
18 Tecnica International LLC by the National Institutes of Health to support open science  
19 research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc.  
20 and as an advisor to Neuron23 Inc.

21

## 1 **Supplementary material**

- 2 Supplementary Table 1. Study population for pathway specific PRS analysis of NLRP3
- 3 inflammasome genes
- 4 Supplementary Table 2. Pathway specific polygenic risk score analysis on the of NLRP3
- 5 inflammasome in Parkinson's disease
- 6 Supplementary Table 3. Study population for rare variant analysis
- 7 Supplementary Table 4. Burden analysis of rare variants in NLRP3 inflammasome related
- 8 genes
- 9 Supplementary Table 5. Summary based Mendelian randomization studies between NLRP3
- 10 related genes expression loci and Parkinson's disease risk and progression
- 11 Supplementary Table 6. GP2 study population for the role of common variants in NLRP3
- 12 inflammasome genes



## 1     **References**


- 2     1.     Jewell, S., Herath, A.M. & Gordon, R. Inflammasome Activation in Parkinson's Disease. *J*  
3     *Parkinsons Dis* **12**, S113-s128 (2022).
- 4     2.     Haque, M.E., *et al.* Targeting the microglial NLRP3 inflammasome and its role in Parkinson's  
5     disease. *Mov Disord* **35**, 20-33 (2020).
- 6     3.     Codolo, G., *et al.* Triggering of inflammasome by aggregated  $\alpha$ -synuclein, an inflammatory  
7     response in synucleinopathies. *PLoS one* **8**, e55375 (2013).
- 8     4.     Gustot, A., *et al.* Amyloid fibrils are the molecular trigger of inflammation in Parkinson's  
9     disease. *Biochem J* **471**, 323-333 (2015).
- 10    5.     Shao, Q.H., Zhang, X.L., Yang, P.F., Yuan, Y.H. & Chen, N.H. Amyloidogenic proteins  
11    associated with neurodegenerative diseases activate the NLRP3 inflammasome. *Int*  
12    *Immunopharmacol* **49**, 155-160 (2017).
- 13    6.     Mao, Z., *et al.* The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's  
14    Disease in Rats. *Neurochem Res* **42**, 1104-1115 (2017).
- 15    7.     Sarkar, S., *et al.* Mitochondrial impairment in microglia amplifies NLRP3 inflammasome  
16    proinflammatory signaling in cell culture and animal models of Parkinson's disease. *NPJ*  
17    *Parkinsons Dis* **3**, 30 (2017).
- 18    8.     von Herrmann, K.M., *et al.* NLRP3 expression in mesencephalic neurons and characterization  
19    of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease. *NPJ*  
20    *Parkinsons Dis* **4**, 24 (2018).
- 21    9.     Fan, Z., *et al.* Systemic activation of NLRP3 inflammasome and plasma  $\alpha$ -synuclein levels are  
22    correlated with motor severity and progression in Parkinson's disease. *J Neuroinflammation*  
23    **17**, 11 (2020).
- 24    10.    Anderson, F.L., *et al.* Plasma-borne indicators of inflammasome activity in Parkinson's  
25    disease patients. *NPJ Parkinsons Dis* **7**, 2 (2021).
- 26    11.    Nguyen, L.T.N., *et al.* Role of NLRP3 Inflammasome in Parkinson's Disease and Therapeutic  
27    Considerations. *J Parkinsons Dis* **12**, 2117-2133 (2022).
- 28    12.    Minikel, E.V., Painter, J.L., Dong, C.C. & Nelson, M.R. Refining the impact of genetic evidence  
29    on clinical success. *medRxiv*, 2023.2006.2023.23291765 (2023).
- 30    13.    Nalls, M.A., *et al.* Identification of novel risk loci, causal insights, and heritable risk for  
31    Parkinson's disease: a meta-analysis of genome-wide association studies. *The Lancet*  
32    *Neurology* **18**, 1091-1102 (2019).
- 33    14.    Finan, C., *et al.* The druggable genome and support for target identification and validation in  
34    drug development. *Sci Transl Med* **9**(2017).
- 35    15.    Consortium, G. The GTEx Consortium atlas of genetic regulatory effects across human  
36    tissues. *Science* **369**, 1318-1330 (2020).
- 37    16.    Wang, D., *et al.* Comprehensive functional genomic resource and integrative model for the  
38    human brain. *Science* **362**, eaat8464 (2018).
- 39    17.    Qi, T., *et al.* Identifying gene targets for brain-related traits using transcriptomic and  
40    methyloomic data from blood. *Nature communications* **9**, 2282 (2018).
- 41    18.    Blauwendraat, C., *et al.* Parkinson's disease age at onset genome-wide association study:  
42    Defining heritability, genetic loci, and  $\alpha$ -synuclein mechanisms. *Mov Disord* **34**, 866-875  
43    (2019).
- 44    19.    Iwaki, H., *et al.* Genomewide association study of Parkinson's disease clinical biomarkers in  
45    12 longitudinal patients' cohorts. *Mov Disord* **34**, 1839-1850 (2019).
- 46    20.    Tan, M.M.X., *et al.* Genome-Wide Association Studies of Cognitive and Motor Progression in  
47    Parkinson's Disease. *Mov Disord* **36**, 424-433 (2021).
- 48    21.    Kang, X., *et al.* Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian  
49    Randomization Study. *Neurology* **96**, e1672-e1679 (2021).
- 50    22.    McFarthing, K., *et al.* Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023  
51    Update. *J Parkinsons Dis* **13**, 427-439 (2023).
- 52    23.    Pruim, R.J., *et al.* LocusZoom: regional visualization of genome-wide association scan results.  
53    *Bioinformatics* **26**, 2336-2337 (2010).
- 54    24.    Choi, S.W., *et al.* PRSet: Pathway-based polygenic risk score analyses and software. *PLoS*  
55    *genetics* **19**, e1010624 (2023).

- 1 25. Iwaki, H., *et al.* Accelerating medicines partnership: Parkinson's disease. genetic resource.  
2 *Movement Disorders* **36**, 1795-1804 (2021).
- 3 26. Carson, A.R., *et al.* Effective filtering strategies to improve data quality from population-  
4 based whole exome sequencing studies. *BMC Bioinformatics* **15**, 125 (2014).
- 5 27. Lee, S., *et al.* Optimal unified approach for rare-variant association testing with application  
6 to small-sample case-control whole-exome sequencing studies. *The American Journal of*  
7 *Human Genetics* **91**, 224-237 (2012).
- 8 28. Lee, S., Teslovich, T.M., Boehnke, M. & Lin, X. General framework for meta-analysis of rare  
9 variants in sequencing association studies. *The American Journal of Human Genetics* **93**, 42-  
10 53 (2013).
- 11 29. Zhu, Z., *et al.* Integration of summary data from GWAS and eQTL studies predicts complex  
12 trait gene targets. *Nature genetics* **48**, 481-487 (2016).
- 13 30. Wu, Y., *et al.* Integrative analysis of omics summary data reveals putative mechanisms  
14 underlying complex traits. *Nature communications* **9**, 918 (2018).

15

16


1



2

3 **Figure 1. Locus zoom plot of *NLRP3*, *CASP1*, *PYCARD*, *IL-1β* and *IL-18* genes (+/- 500**  
 4 **kb) in Parkinson's disease GWAS.**

5 The SNP with the lowest P-value in the studied gene or locus is highlighted by red square.  
 6 The punctuated line represents GWAS level of significance  $p < 5 \times 10^{-8}$ . SNPs shown in grey  
 7 are below this significance level, while those in blue exceed it. X-axis: Chromosomal  
 8 position (in Mb). Y-axis: Negative log10 of the P-values from GWAS.



9

10 **Figure 2. Pathway specific PRS analysis of *NLRP3* inflammasome genes.**

11 OR- odds ratio; CI- confidence interval; PPMI- Parkinson's Progression Markers Initiative;  
 12 APDGC- Autopsy-Confirmed Parkinson Disease GWAS Consortium; IPDGC -International  
 13 Parkinson Disease Genomics Consortium; NINDS- National Institute of Neurological  
 14 Disorders and Stroke Repository Parkinson's Disease Collection, NGRC- NeuroGenetics  
 15 Research Consortium; UKBB-UK Biobank